Gastroesophageal reflux disease medication
Pro Research Analysisby 
Searched over 200M research papers
Gastroesophageal Reflux Disease Medication: An Overview
Introduction to GERD and Its Prevalence
Gastroesophageal reflux disease (GERD) is a prevalent gastrointestinal disorder characterized by the reflux of stomach contents into the esophagus, leading to symptoms such as heartburn and regurgitation 49. The condition is widespread, particularly in North America and East Asia, and is managed by both gastroenterologists and primary care physicians .
Proton Pump Inhibitors (PPIs): The Mainstay of GERD Treatment
Efficacy and Usage
Proton pump inhibitors (PPIs) have been the cornerstone of GERD treatment for the past three decades. They are highly effective in reducing gastric acid production and are recommended as first-line therapy for GERD 410. PPIs such as omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole are commonly used .
Adverse Effects and Concerns
Despite their efficacy, there is growing concern about the potential adverse effects of long-term PPI use. These include risks of kidney injury, metabolic bone disease, myocardial infarction, and even dementia . Additionally, PPIs have been associated with an increased risk of lower respiratory tract infections and nosocomial sepsis in immune-deficient children .
Histamine-2 Receptor Antagonists (H2RAs)
Usage and Effectiveness
Histamine-2 receptor antagonists (H2RAs), including ranitidine, cimetidine, famotidine, and nizatidine, have been used to treat GERD, particularly in pediatric patients. However, they are generally less effective than PPIs in relieving symptoms and healing GERD 15.
Safety Concerns
In April 2020, the FDA and EMA requested the removal of all ranitidine products from the market due to potential carcinogenic risks . Adverse effects of H2RAs include headaches, diarrhea, and nausea, with a reported incidence of at least 23% in treated patients .
Baclofen: An Alternative Therapeutic Option
Baclofen, a GABA agonist, has shown promise in relieving GERD symptoms, particularly in PPI-resistant patients. It can improve reflux symptoms and pH-monitoring findings, although its effect on pH-monitoring parameters is less significant . However, baclofen's side effects, including mild neurological and mental status deterioration, limit its widespread use .
Emerging Therapies and Unmet Needs
Vonoprazan and Potassium-Competitive Acid Blockers
Vonoprazan, a new potassium-competitive acid blocker, has been launched in Japan and shows potential in healing GERD. It may offer an alternative to traditional PPIs, although further comparative studies are needed 47.
Mucosal Protective Compounds
Drugs with protective action on the esophageal mucosa, such as sucralfate, alginate-antacid combinations, and guaiazulene-dimethicone, have been used to alleviate GERD symptoms. These compounds can be particularly useful in patients with mild reflux symptoms or those who do not respond adequately to acid suppression therapy .
Conclusion
The management of GERD involves a combination of lifestyle modifications and pharmacological therapy. While PPIs remain the mainstay of treatment, concerns about their long-term safety have led to the exploration of alternative therapies such as baclofen, vonoprazan, and mucosal protective compounds. Further research is needed to develop novel antisecretory drugs with proven efficacy and safety profiles, particularly for pediatric patients and those with refractory GERD.
Sources and full results
Most relevant research papers on this topic
Which drugs are risk factors for the development of gastroesophageal reflux disease?
Drugs like nitrates, calcium channel blockers, and benzodiazepines can increase the risk of developing or exacerbating gastroesophageal reflux disease.
DOI